Replies to post #10208 on Arch Therapeutics Inc (ARTH)

[blackngold63]

Someone with ties to J&J used to be on Arch's board. Or high up. So others out there in the industry are aware of Arth. They may think what a lot of us do as well - that the money is in the internal product, not the external. There is too much present or potential competition with that product. If it were part of a line of products, well that is one thing. But as a stand alone..........

Another problem is Covid. It can flare up at any time. Internal trials with that looming over your head - it obviously increases the expense but who wants to even get involved in them on any level..? From the participants to the doctors who would have to run them..? People got better things to do. Arch needed to get the train out of the station before Covid and they didn't.

[Polyphemus]

Wound dressings do not 'cure' diabetic foot ulcers or prevent amputations. This is a more complicated problem, currently without an adequate solution. Such a solution will most likely involve both surgery & Rx drugs as the central issues, with wound dressings as a minor but important issue. Those wound dressings already exist.

[Polyphemus]

Wound dressings do not 'cure' diabetic foot ulcers or prevent amputations. This is a more complicated problem, currently without an adequate solution. Such a solution will most likely involve both surgery & Rx drugs as the central issues, with wound dressings as a minor but important issue. Those wound dressings already exist.